The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection.
The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection.
复制标题
DOI：
10.1101/2020.06.15.153387
复制
发表时间：
2021-01-01
期刊：
影响因子：
--
通讯作者：
Bix, Gregory J
中科院分区：
文献类型：
--
作者：
Beddingfield, Brandon J;Iwanaga, Naoki;Bix, Gregory J
许多设计和筛选严重急性呼吸综合征冠状病毒 (SARS-CoV-2) 疗法的努力都集中在通过破坏 ACE2 与 SARS-CoV-2 刺突蛋白的结合来抑制病毒细胞进入。这项工作的重点是通过假设的基于 α5β1 整合素的机制抑制 SARS-CoV-2 进入，并表明使用分子 ATN-161 抑制刺突蛋白与 α5β1 整合素 (+/- ACE2) 的相互作用，以及 α5β1 整合素与 ACE2 之间的相互作用代表了治疗 COVID-19 的一种有前途的方法。为设计和筛选当前严重急性呼吸综合征 - 冠状病毒 - 2 的治疗方法做出了许多努力(SARS-CoV-2) 大流行的重点是通过破坏血管紧张素转换酶 2 (ACE2) 与 SARS-CoV-2 刺突蛋白的结合来抑制病毒宿主细胞进入。这项工作重点关注通过假设的基于 α5β1 整合素的机制抑制 SARS-CoV-2 进入的潜力，并表明使用新型分子 (ATN-161) 抑制刺突蛋白与 α5β1 整合素 (+/- ACE2) 的相互作用以及 α5β1 整合素与 ACE2 之间的相互作用是治疗冠状病毒疾病 19 的一种有前途的方法。
Many efforts to design and screen therapeutics for severe acute respiratory syndrome coronavirus (SARS-CoV-2) have focused on inhibiting viral cell entry by disrupting ACE2 binding with the SARS-CoV-2 spike protein. This work focuses on inhibiting SARS-CoV-2 entry through a hypothesized alpha5beta1 integrin-based mechanism, and indicates that inhibiting the spike protein interaction with alpha5beta1 integrin (+/- ACE2), and the interaction between alpha5beta1 integrin and ACE2 using a molecule ATN-161 represents a promising approach to treat COVID-19.Many efforts to design and screen therapeutics for the current severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) pandemic have focused on inhibiting viral host cell entry by disrupting angiotensin-converting enzyme-2 (ACE2) binding with the SARS-CoV-2 spike protein. This work focuses on the potential to inhibit SARS-CoV-2 entry through a hypothesized alpha5beta1 integrin-based mechanism and indicates that inhibiting the spike protein interaction with alpha5beta1 integrin (+/- ACE2) and the interaction between alpha5beta1 integrin and ACE2 using a novel molecule (ATN-161) represents a promising approach to treat coronavirus disease-19.